Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
140 participants
OBSERVATIONAL
2019-02-12
2030-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
The Swiss Childhood Cancer Survivor Study - Follow-up (SCCSS-FollowUp)
NCT04732273
Swiss Childhood Cancer Survivor Study
NCT03297034
Young Survivors at Kantonsspital Aarau, Switzerland
NCT04811794
Childhood Cancer Survivor Study
NCT01120353
The Prospective Observational COMPRAYA Cohort Study
NCT04682470
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Objectives: The main objective of the ACCS study is to identify the current needs of adolescent and young adult long-term survivors in terms of follow-up care by comparing three different transition practices. The secondary objective is to assess survivors' knowledge on their diagnosis, therapy and follow-up examinations longitudinally.
Methods: ACCS is a multicenter questionnaire-based study, including survivors from three pediatric oncology centers in Switzerland. Eligible survivors who already transitioned to adult care at start of the study once receive a letter explaining the purpose of the study, the study information, the informed consent form, and the questionnaire. The questionnaire asks about cancer knowledge and additionally includes validated scales on cancer worry, self-management skills, ongoing care, and expectations. The survivors send the documents back by a prepaid envelope. Eligible survivors before transition to adult care at start of the study receive a letter explaining the purpose of the study, the study information and informed consent form, and the first questionnaire two to four weeks before the next scheduled follow-up visit. They can either send the documents back before the visit or bring them to the visit. The participants receive three month after the visit a short questionnaire to assess cancer knowledge. Three month after the follow-up visit after transition (15 month after last visit in pure pediatric setting), the participants receive the first comprehensive questionnaire again.
Rationale and significance: There are very different aftercare and transition models in Switzerland, although it is unclear which follow-up care strategy best meets the needs of survivors. The data collected within the ACCS study helps to define which transition and follow-up care strategies and related factors are favoured by adolescent and young adult survivors. Adaption of transition processes to the needs of survivors improve adherence to follow-up care of adult childhood cancer survivors. As late effects increase with increasing time from treatment, adult survivors of childhood cancer are at particular risk to develop late effects and it is important that they continue follow-up care.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Transition model
Transition of follow-up care of childhood cancer survivors to adult care
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis according to ICCC3 I-XII; Langerhans cell histiocytosis (LCH), Hemophagocytic lymphohistiocytosis (HLH)
* Age at diagnosis \<18 years
* Age at study ≥16 years
* At study start in follow-up care at one of the three pediatric oncology centers (group before transition) or transitioned not before 2014 (group after transition).
* Written informed consent
Exclusion Criteria
* \<5 years after therapy of a relapse or palliative situation
* Severe cognitive impairment, which makes it impossible to complete the questionnaire independently
* Insufficient knowledge of the German language
* Informed consent form not signed
16 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University Children's Hospital Basel
OTHER
Luzerner Kantonsspital
OTHER
Kantonsspital Aarau
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Katrin Scheinemann
Division Head of Pediatric Oncology-Hematology
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Katrin Scheinemann, MD
Role: PRINCIPAL_INVESTIGATOR
Kantonsspital Aarau
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Division of Oncology - Hematology, Department of Pediatrics, Kantonsspital Aarau
Aarau, , Switzerland
Division of Oncology/ Hematology, University Children's Hospital Basel
Basel, , Switzerland
Division of Oncology/ Hematology, Department of Pediatrics, Kantonsspital Lucerne
Lucerne, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Katrin Scheinemann, MD
Role: primary
Tamara Diesch, MD
Role: primary
Bernhard Eisenreich, MD
Role: primary
References
Explore related publications, articles, or registry entries linked to this study.
Denzler S, Otth M, Scheinemann K. Aftercare of Childhood Cancer Survivors in Switzerland: Protocol for a Prospective Multicenter Observational Study. JMIR Res Protoc. 2020 Aug 26;9(8):e18898. doi: 10.2196/18898.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2018-02304
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.